BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Rindopepimut: Phase III started

Celldex began the double-blind, international Phase III ACT IV trial in 440 patients to compare rindopepimut with granulocyte macrophage colony-stimulating factor (GM-CSF) plus Temodar temozolomide vs. Temodar alone. Patients will receive...

Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >